Evidence map›Paper›PMID 28819209›Full record

ArticleScientific reports2017

Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) for the Treatment of Unresectable and Metastatic Cancers.

Yang Liu, Paolo Maccarini, Gregory M Palmer, Wiguins Etienne, Yulin Zhao, Chen-Ting Lee, Xiumei Ma, Brant A Inman, Tuan Vo-Dinh

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 141 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Gold Nanostars Obviate Limitations to Laser Interstitial Thermal Therapy (LITT) for the Treatment of Intracranial Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  14. Article
  15. Review
  16. Immunogenic Cell Death in Hematological Malignancy Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Review
  17. Article
  18. Review
  19. Article
  20. Synergistic effect of arginine andIranian journal of basic medical sciences · 2023
    Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yang LiuDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
Paolo MaccariniDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
Gregory M PalmerDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC, 27710, USA.
Wiguins EtienneDepartment of Surgery, Duke University Medical Center, Durham, NC, 27710, USA.
Yulin ZhaoDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC, 27710, USA.
Chen-Ting LeeDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC, 27710, USA.
Xiumei MaDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC, 27710, USA.
Brant A InmanDepartment of Surgery, Duke University Medical Center, Durham, NC, 27710, USA. brant.inman@duke.edu.ORCID 0000-0002-6060-4485
Tuan Vo-DinhDepartment of Biomedical Engineering, Duke University, Durham, NC, 27708, USA. tuan.vodinh@duke.edu.ORCID 0000-0003-3701-3326
Duke Medical Center · USDuke University · US

Funding

Plasmonic nanoparticle-mediated immunotherapy to treat metastatic cancerR01EB028078 · NIBIB · DUKE UNIVERSITY · PI VO-DINH, TUAN · 2019 to 2022
$2.1M
NIBIB NIH HHS R01 EB028078
6 · The paper itself

Abstract

Metastatic spread is the mechanism in more than 90 percent of cancer deaths and current therapeutic options, such as systemic chemotherapy, are often ineffective. Here we provide a proof of principle for a novel two-pronged modality referred to as Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) having the potential to safely eradicate both primary tumors and distant metastatic foci. Using a combination of immune-checkpoint inhibition and plasmonic gold nanostar (GNS)-mediated photothermal therapy, we were able to achieve complete eradication of primary treated tumors and distant untreated tumors in some mice implanted with the MB49 bladder cancer cells. Delayed rechallenge with MB49 cancer cells injection in mice that appeared cured by SYMPHONY did not lead to new tumor formation after 60 days observation, indicating that SYMPHONY treatment induced effective long-lasting immunity against MB49 cancer cells.

Indexed as

Hyperthermia, InducedPhototherapyTheranostic NanomedicineAnimalsImmunophenotypingKaplan-Meier EstimateMiceNeoplasm MetastasisUrinary Bladder Neoplasms

Identifiers

PMID28819209
PMCPMC5561243
OpenAlexW2742803722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.